ERIC KONDRO: Open Payments
NPI 1336124023 · MONTGOMERY CITY, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$725 in 39 payments from 13 companies in 2025. Trend: 2023 $295 · 2024 $543 · 2025 $725
Food & beverage: $725
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 10 | $182 |
| Vanda Pharmaceuticals Inc. | 7 | $144 |
| Alkermes, Inc. | 5 | $94 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $87 |
| Otsuka America Pharmaceutical, Inc. | 2 | $45 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $37 |
| Teva Pharmaceuticals USA, Inc. | 2 | $30 |
| Bayer Healthcare Pharmaceuticals Inc. | 1 | $19 |
| Viatris Specialty LLC | 1 | $19 |
| Aimmune Therapeutics, Inc. | 1 | $19 |
Products named: INGREZZA, FANAPT, CAPLYTA, ARISTADA, REXULTI, JARDIANCE, UZEDY, Kerendia.
Industry payments across MO — which companies pay providers there.
